Haemoglobinopathies, Coagulopathies and Inborn errors of metabolism

For these areas of our scope, we worked closely with our clinical editors and consumer peer reviewers to identify topics of interest and develop review questions based on these areas. We also closely followed new therapies and trials in each of the areas of our scope and regularly interrogated our respective trials registers to identify areas where there was evidence but not yet any review. We then collaborated with our stakeholders to establish how these could generate relevant priority reviews. We were previously in contact with the authors of the James Lind PSP on bleeding disorders which we hoped would provide additional coagulopathy priority topics and review titles.

You can view a list of all our previous vacant priority titles here.